The landscape of chromothripsis across adult cancer types.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 05 2020
Historique:
received: 01 12 2019
accepted: 17 03 2020
entrez: 10 5 2020
pubmed: 10 5 2020
medline: 18 8 2020
Statut: epublish

Résumé

Chromothripsis is a recently identified mutational phenomenon, by which a presumably single catastrophic event generates extensive genomic rearrangements of one or a few chromosome(s). Considered as an early event in tumour development, this form of genome instability plays a prominent role in tumour onset. Chromothripsis prevalence might have been underestimated when using low-resolution methods, and pan-cancer studies based on sequencing are rare. Here we analyse chromothripsis in 28 tumour types covering all major adult cancers (634 tumours, 316 whole-genome and 318 whole-exome sequences). We show that chromothripsis affects a substantial proportion of human cancers, with a prevalence of 49% across all cases. Chromothripsis generates entity-specific genomic alterations driving tumour development, including clinically relevant druggable fusions. Chromothripsis is linked with specific telomere patterns and univocal mutational signatures in distinct tumour entities. Longitudinal analysis of chromothriptic patterns in 24 matched tumour pairs reveals insights in the clonal evolution of tumours with chromothripsis.

Identifiants

pubmed: 32385320
doi: 10.1038/s41467-020-16134-7
pii: 10.1038/s41467-020-16134-7
pmc: PMC7210959
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2320

Références

Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
pubmed: 21215367 pmcid: 21215367
Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59–71 (2012).
pubmed: 22265402 pmcid: 3332216
Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226–1236 (2013).
pubmed: 23498933
Fontana, M. C. et al. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia 32, 1609–1620 (2018).
pubmed: 29472722 pmcid: 6035145
Rucker, F. G. et al. Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. Haematologica 103, e17–e20 (2018).
pubmed: 29079594 pmcid: 5777208
Molenaar, J. J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589–593 (2012).
pubmed: 22367537
Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
pubmed: 25351503 pmcid: 4596003
Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378–382 (2016).
pubmed: 27732578 pmcid: 5446075
Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758–769 e759 (2018).
pubmed: 6425931 pmcid: 6425931
Chudasama, P. et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat. Commun. 9, 144 (2018).
pubmed: 29321523 pmcid: 5762758
Rode, A., Maass, K. K., Willmund, K. V., Lichter, P. & Ernst, A. Chromothripsis in cancer cells: an update. Int. J. cancer 138, 2322–2333 (2016).
pubmed: 26455580
Cancer Genome Atlas, N. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
Cai, H. et al. Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens. BMC Genomics 15, 82 (2014).
pubmed: 24476156 pmcid: 3909908
Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature https://doi.org/10.1038/nature25480 (2018).
Cortes-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. https://doi.org/10.1038/s41588-019-0576-7 (2020).
Horak, P. et al. Precision oncology based on omics data: The NCT Heidelberg experience. Int. J. Cancer 141, 877–886 (2017).
pubmed: 28597939
Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).
pubmed: 31444325 pmcid: 6707220
Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J. & de Lange, T. Chromothripsis and kataegis induced by telomere crisis. Cell 163, 1641–1654 (2015).
pubmed: 26687355 pmcid: 4687025
Li, Y. et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508, 98–102 (2014).
pubmed: 24670643 pmcid: 3976272
Ernst, A. et al. Telomere dysfunction and chromothripsis. Int. J. Cancer 138, 2905–2914 (2016).
pubmed: 26856307
Zhang, C. Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179–184 (2015).
pubmed: 26017310 pmcid: 4742237
Ly, P. et al. Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining. Nat. Cell Biol. 19, 68–75 (2017).
pubmed: 27918550
Waszak, S. M. et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 19, 785–798 (2018).
pubmed: 29753700 pmcid: 5984248
Ratnaparkhe, M. et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia 31, 2048–2056 (2017).
pubmed: 28196983
Persson, M. et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl Acad. Sci. USA 106, 18740–18744 (2009).
pubmed: 19841262
Mitani, Y. et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 16, 4722–4731 (2010).
pubmed: 20702610 pmcid: 5862426
Mardin, B. R. et al. A cell-based model system links chromothripsis with hyperploidy. Mol. Syst. Biol. 11, 828 (2015).
pubmed: 26415501 pmcid: 4592670
Zhang, A. et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 60, 6230–6235 (2000).
pubmed: 11103775
Peifer, M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704 (2015).
pubmed: 26466568 pmcid: 4881306
Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961 (2013).
pubmed: 23348503
Cesare, A. J. & Reddel, R. R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat. Rev. Genet. 11, 319–330 (2010).
pubmed: 20351727
Ratnaparkhe, M. et al. Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. Nat. Commun. 9, 4760 (2018).
pubmed: 30420702 pmcid: 6232171
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 3776390
Bassaganyas, L. et al. Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia 27, 2376–2379 (2013).
pubmed: 23612016 pmcid: 3865532
Lee, J. J. et al. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell 177, 1842–1857 e1821 (2019).
pubmed: 31155235
Reisinger, E. et al. OTP: An automatized system for managing and processing NGS data. J. Biotechnol. 261, 53–62 (2017).
pubmed: 28803971
Jones, D. T. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927–932 (2013).
pubmed: 23817572 pmcid: 3951336
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
pubmed: 29535149 pmcid: 5880247
Kleinheinz, K. et al. ACEseq – allele specific copy number estimation from whole genome sequencing. BioRxiv. 210807 (2017).
D’Aurizio, R. et al. Enhanced copy number variants detection from whole-exome sequencing data using EXCAVATOR2. Nucleic Acids Res. 44, e154 (2016).
pubmed: 27507884 pmcid: 5175347
Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).
pubmed: 25017105 pmcid: 4753679
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 pmcid: 3833702
Alexandrov, L. The Repertoire of mutational signatures in human cancer. Environ. Mol. Mutagen 59, 25–25 (2018).
Daniel, H., Zuguang, G. & Matthias, S. YAPSA: Yet Another Package for Signature Analysis. https://www.bioconductor.org/packages/release/bioc/html/YAPSA.html (2018).
Feuerbach, L. et al. TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. BMC Bioinforma. 20, 272 (2019).
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
pubmed: 29535149 pmcid: 5880247
Bunn, A. & Korpela, M. R: A Language and Environment for Statistical Computing (RC Team, 2018).
Ginestet, C. ggplot2: elegant graphics for data analysis. J. R. Stat. Soc. a Stat. 174, 245–245 (2011).

Auteurs

Natalia Voronina (N)

Group Genome Instability in Tumors, DKFZ, Heidelberg, Germany.
Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

John K L Wong (JKL)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Daniel Hübschmann (D)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
Heidelberg Institute for Stem cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.
Department of Pediatric Immunology, Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Mario Hlevnjak (M)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.

Sebastian Uhrig (S)

Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Christoph E Heilig (CE)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Peter Horak (P)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Simon Kreutzfeldt (S)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Andreas Mock (A)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Barbara Hutter (B)

Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.

Martina Fröhlich (M)

Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.

Benedikt Brors (B)

Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.

Arne Jahn (A)

Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, German Cancer Consortium (DKTK), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Dresden, Germany.
Department of Translational Medical Oncology, NCT Dresden, Dresden, and DKFZ, Dresden, Germany.
Center for Personalized Oncology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Dresden, Germany.

Barbara Klink (B)

Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, German Cancer Consortium (DKTK), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Dresden, Germany.
National Center of Genetics (NCG), Laboratoire national de santé (LNS), Dudelange, Luxembourg.

Laura Gieldon (L)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Lina Sieverling (L)

Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.

Lars Feuerbach (L)

Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.

Priya Chudasama (P)

Precision Sarcoma Research Group, DKFZ, National Center for Tumor (NCT) Diseases, Heidelberg, Germany.

Katja Beck (K)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Matthias Kroiss (M)

Department of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital Würzburg, Würzburg, Germany.

Christoph Heining (C)

Department of Translational Medical Oncology, NCT Dresden, Dresden, and DKFZ, Dresden, Germany.
Center for Personalized Oncology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Dresden, Germany.

Lino Möhrmann (L)

Department of Translational Medical Oncology, NCT Dresden, Dresden, and DKFZ, Dresden, Germany.
Center for Personalized Oncology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Dresden, Germany.

Andrea Fischer (A)

Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, German Cancer Consortium (DKTK), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Dresden, Germany.

Evelin Schröck (E)

Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, German Cancer Consortium (DKTK), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Dresden, Germany.

Hanno Glimm (H)

Department of Translational Medical Oncology, NCT Dresden, Dresden, and DKFZ, Dresden, Germany.
Center for Personalized Oncology, University Hospital Carl Gustav Carus Dresden, Technical University of Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Dresden, Germany.

Marc Zapatka (M)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Peter Lichter (P)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Stefan Fröhling (S)

German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.

Aurélie Ernst (A)

Group Genome Instability in Tumors, DKFZ, Heidelberg, Germany. a.ernst@dkfz.de.
Division of Molecular Genetics, DKFZ, Heidelberg, Germany. a.ernst@dkfz.de.
German Cancer Consortium (DKTK), Heidelberg, Germany. a.ernst@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH